Complement Pathway Modulators Inhibiting Factor B for AMD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical therapies are inadequate for treating dry age-related macular degeneration, and many patients with neovascular AMD progress to legal blindness despite treatment with anti-VEGF agents, highlighting the need for effective therapeutic agents that modulate the complement alternative pathway.
Innovation Solution
Development of compounds that inhibit Factor B activity, specifically targeting the alternative complement pathway to suppress C3 activation and thereby reduce the amplification of the complement system, which can be used in pharmaceutical compositions for treating complement-mediated diseases including AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-VEGF agents are used to treat neovascular AMD, then vascular leakage is reduced, but patients still progress to legal blindness
Solution Approach 1:
The patent introduces complement pathway modulators as intermediary substances that intervene between the harmful complement activation and the desired therapeutic outcome. These modulators specifically target and inhibit alternative complement pathway enzymes, serving as a mediator to stop the damaging cascade while preserving beneficial immune functions.
Solution Approach 2:
The patent changes the therapeutic parameter by shifting from anti-VEGF alone to a combination approach that includes complement pathway inhibition. This parameter change involves targeting a different biological pathway (complement alternative pathway) to achieve additional therapeutic effects that anti-VEGF agents cannot provide alone.
2Object-generated harmful factors
If the complement alternative pathway is inhibited, then C3 activation and amplification are suppressed, but the mechanism for achieving this inhibition must be developed
Solution Approach 1:
The patent extracts and isolates specific critical enzymes from the complement alternative pathway (such as Factor B and associated proteins) as target objects for inhibition. By identifying and focusing on these specific molecular targets, the complex complement system is broken down into manageable inhibition points that can be addressed with specific therapeutic compounds.
Solution Approach 2:
The patent replaces the need for complex mechanical or surgical interventions with molecular-level chemical inhibition. Instead of physically removing or mechanically blocking complement components, the invention uses pharmacological compounds that bind to and inhibit specific enzymatic activities, substituting a simpler chemical mechanism for complex physical intervention.
3Reliability
If Factor B activity is inhibited, then alternative complement pathway activation is reduced, but specific high-affinity inhibitors must be developed
Solution Approach 1:
The patent changes the parameter of binding affinity by designing inhibitors with high affinity for Factor B and related proteins. This parameter change involves optimizing the chemical structure and interaction characteristics of the inhibitors to ensure strong, specific binding to the target enzymes, thereby achieving reliable pathway inhibition.
Solution Approach 2:
The patent develops inhibitors that can target multiple components of the alternative complement pathway (including Factor B and associated proteins) with a single therapeutic approach. This multi-functionality allows one class of compounds to inhibit multiple enzymes in the pathway, simplifying the development process while maintaining high efficacy.
Data Source
AI summary
The present invention provides a compound of formula I:a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.